“Kristen’s leadership and proven track record for delivering data-driven solutions for our clients is invaluable to the firm” said Matt Riordan, Partner & Chief Operating Officer. “Her commitment and dedication to working with clients to address their most important and complex challenges is exemplary and we are proud to add Kristen to our senior leadership ranks.”
Kristen serves pharmaceutical and biotechnology clients across a range of specialty therapeutic areas including neurology, oncology, hematology, dermatology, and immunology and has worked on engagements that span portfolio optimization, product forecasting, pricing and market access, and strategic brand planning. The majority of Kristen’s work focuses on novel therapies for rare, neurodegenerative, and / or neuromuscular conditions. Prior to joining Putnam, Kristen worked in the medical technology industry where she specialized in market development strategies for stem cell-based technologies. Kristen earned her Ph.D. in Biomedical Engineering from Columbia University, B.S. in Materials Engineering and Biomedical Engineering from Carnegie Mellon University, and completed post-doctoral training at Duke University. Throughout her academic career, Kristen’s research focused on the development of stem cell-based, regenerative therapies. Kristen received a National Science Foundation Pre-Doctoral Fellowship, earned dissertation distinction, and was awarded several national honors for her research. Kristen has authored numerous peer-reviewed publications and book chapters and has several technology patents. Kristen has also served as a consultant to biomedical-focused venture capital, business development, and investment firms.